Company / PP&E (Net)
NewAmsterdam Pharma Co N.V. PP&E (Net) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$383.0K
FY2025
5-year range
$34.0K / $383.0K
FY2022-FY2025
Trend
+58.3%
vs FY2024
Sector context
#177 of 197
Health Care
What the data says
Among 197 Health Care companies, NewAmsterdam Pharma Co N.V. is in the bottom 10% for pp&e (net). PP&E (Net) has increased for 3 consecutive years, from $34,000 in FY2022 to $383,000 in FY2025.
Based on SEC 10-K filings.
$383,000 in FY2025 with a 3-year CAGR of +124.2%.
Improved from $46,000 to $383,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +124.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 197This company $383.0K Sector average $773.5M
▼
-100.0% below sector average
Key checks
Key Insights
- NewAmsterdam Pharma Co N.V.'s pp&e (net) has grown for 3 consecutive years.
- 3-year CAGR of +124.2%, indicating consistent growth.
- In FY2025, pp&e (net) increased 58.3% year-over-year.
- Ranks #177 out of 197 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $383.0K | +58.3% |
| FY2024 | $242.0K | +426.1% |
| FY2023 | $46.0K | +35.3% |
| FY2022 | $34.0K | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026